Cargando…
Clinical value of next generation sequencing of plasma cell-free DNA in gastrointestinal stromal tumors
BACKGROUND: Gastrointestinal stromal tumor (GIST) initiation and evolution is commonly framed by KIT/PDGFRA oncogenic activation, and in later stages by the polyclonal expansion of resistant subpopulations harboring KIT secondary mutations after the onset of imatinib resistance. Thus, circulating tu...
Autores principales: | Serrano, César, Vivancos, Ana, López-Pousa, Antonio, Matito, Judit, Mancuso, Francesco M., Valverde, Claudia, Quiroga, Sergi, Landolfi, Stefania, Castro, Sandra, Dopazo, Cristina, Sebio, Ana, Virgili, Anna C., Menso, María M., Martín-Broto, Javier, Sansó, Miriam, García-Valverde, Alfonso, Rosell, Jordi, Fletcher, Jonathan A., George, Suzanne, Carles, Joan, Arribas, Joaquín |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7003348/ https://www.ncbi.nlm.nih.gov/pubmed/32024476 http://dx.doi.org/10.1186/s12885-020-6597-x |
Ejemplares similares
-
SEOM-GEIS clinical guideline for gastrointestinal stromal tumors (2022)
por: Serrano, César, et al.
Publicado: (2023) -
Pharmacogenetic Profiling in High-Risk Soft Tissue Sarcomas Treated with Neoadjuvant Chemotherapy
por: Virgili Manrique, Anna C., et al.
Publicado: (2022) -
Silencing of adaptor protein SH3BP2 reduces KIT/PDGFRA receptors expression and impairs gastrointestinal stromal tumors growth
por: Serrano‐Candelas, Eva, et al.
Publicado: (2018) -
2023 GEIS Guidelines for gastrointestinal stromal tumors
por: Serrano, César, et al.
Publicado: (2023) -
Dovitinib in patients with gastrointestinal stromal tumour refractory and/or intolerant to imatinib
por: Joensuu, Heikki, et al.
Publicado: (2017)